Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Inflation Reduction Act (IRA) boosts biological drugs

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 22, 2024 1:19pm

67 Views

Post# 36101656

RE:RE:RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs

June 20, 2024 - "“As dealmakers become more comfortable with regulatory uncertainty, we’ve seen dealmakers increasingly focused on deals in the $5 billion to $15 billion range rather than in large-scale transformative M&A,” Roel Van den Akker, PwC’s Pharma and Life Sciences Seals Lead, said

https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=36097745

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks